Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pancreatic Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Gemcitabine 10Docetaxel 5Mitomycin 4erdafitinib 3durvalumab 3Cystoscopy 3disitamab vedotin 2BCG Vaccine 25-aminolevulinic acid hexyl ester 2tremelimumab 1tislelizumab 1monalizumab 1dodecyl maltoside 1chondroitin sulfate, sodium hyaluronate drug combination 1bicalutamide 1Urine Specimen Collection 1Transurethral Resection of Bladder 1Therapeutic Uses 1Surveys and Questionnaires 1Saline Solution 1Patient Discharge 1Paclitaxel 1Nonsteroidal Anti-Androgens 1Monatide (IMS 3015) 1Mitozytrex 1Metformin 1Magnetic Resonance Spectroscopy 1Laser Therapy 1Hyaluronic Acid 1House Calls 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Non-Muscle Invasive Bladder Neoplasms × 1-phenyl-3,3-dimethyltriazene × Clear all
NCT03945162 2025-11-24

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

TheralaseĀ® Technologies Inc.

Phase 2 Recruiting
90 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚔